About Sêmeia
Sêmeia is a Healthcare company founded in 2017 by Daniel Szeftel and Pierre Hornus. AI-based patient monitoring software is provided for healthcare. It operates on a SaaS (Software-as-a-Service) and HealthTech model. Sêmeia has raised $8.39 million across 2 funding rounds from investors including Banque des Territoires, Orange Ventures and Malakoff Humanis. Its chief executive, as recorded, is Pierre Hornus. Sêmeia offers products and services including NephroWise, MentalWise, OncoWise, CardioWise, and PneumoWise. Its focus areas include Digital Health and Telehealth.
Company details
Sêmeia is engaged in providing telemonitoring solutions for patients with chronic conditions. Various sectors such as nephrology, oncology, mental health, cardiology, pneumology, and rheumatology are covered by their specialized products. Data security and AI-driven risk prediction are integrated to enhance personalized care plans. Patient data is managed securely with direct communication tools like chat and teleconsultation. The solutions are designed to improve care quality and reduce hospitalizations by enabling timely medical interventions.
- Total Equity Funding$8.39M (USD)
in 2 rounds
- InvestorsBanque des Territoires
& 3 more
Products & Services of Sêmeia
Sêmeia offers a comprehensive portfolio of products and services, including NephroWise, MentalWise, OncoWise, CardioWise, and PneumoWise.
Patient monitoring for kidney transplant and insufficiency cases.
Mental health tracking for bipolar and depression patients.
Oncology patient follow-up for breast and prostate cancer.
Cardiac care monitoring for heart failure and diabetes.
Respiratory monitoring for asthma and sleep apnea patients.
Rheumatology tracking for patients with rheumatoid arthritis issues.
Funding Insights of Sêmeia
Sêmeia has successfully raised a total of $8.39M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.39M
- Total Rounds 2
- First Round $8.39M
(Dec 2022)
- Investors Count 4
All 2 funding rounds of Sêmeia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | Series A | – | – | ||
| Dec 2022 | $8.39M | Series A | – | – |
4 investors in total: 4 institutional.
Investors in Sêmeia
Sêmeia has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Banque des Territoires, Orange Ventures and Malakoff Humanis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are directed toward startups and early-stage companies. | ventures.orange.com | Paris, France | ||
| xange.vc | ||||
Offers insurance, savings, and retirement services for individuals, enterprises, and independents. | 1981 | malakoffhumanis.com | Paris, France | |
Legal and finance advisory services are provided to clients. | 2018 | banquedesterritoires.fr | Paris, France |
Investor details for Sêmeia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sêmeia
2 people are tracked at Sêmeia (2 in leadership).
| Name | Role | Group |
|---|---|---|
Daniel Szeftel | Co-Founder | Leadership |
Pierre Hornus | Co-Founder & CEO | Leadership |
Complete people profiles for Sêmeia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sêmeia
3 dated milestones of Sêmeia across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Sêmeia is founded.
- Funding First funding round of $8.4M.
- Funding Latest funding round, Series A,.
Web traffic of Sêmeia
The website of Sêmeia (semeia.io) receives about 6.2K visits a month.
- Monthly visits6.2K
▼ 43.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sêmeia
Complete news archive for Sêmeia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sêmeia
Sêmeia was founded in 2017 and raised its 1st funding round 5 years after it was founded.
Pierre Hornus is the CEO of Sêmeia, as recorded in our data. They have also founded this company.
Sêmeia is a funded company, having raised a total of $8.39M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.39M, raised on Dec 2022.
Sêmeia is engaged in providing telemonitoring solutions for patients with chronic conditions. Various sectors such as nephrology, oncology, mental health, cardiology, pneumology, and rheumatology are covered by their specialized products. Data security and AI-driven risk prediction are integrated to enhance personalized care plans. Patient data is managed securely with direct communication tools like chat and teleconsultation. The solutions are designed to improve care quality and reduce hospitalizations by enabling timely medical interventions.
Sêmeia offers NephroWise, MentalWise, OncoWise, CardioWise, and 2 more products and services.
Sêmeia has 4 investors. Key investors include Banque des Territoires, Orange Ventures, Malakoff Humanis, and XAnge.